JP6253986B2 - コレクション及びその使用方法 - Google Patents

コレクション及びその使用方法 Download PDF

Info

Publication number
JP6253986B2
JP6253986B2 JP2013539286A JP2013539286A JP6253986B2 JP 6253986 B2 JP6253986 B2 JP 6253986B2 JP 2013539286 A JP2013539286 A JP 2013539286A JP 2013539286 A JP2013539286 A JP 2013539286A JP 6253986 B2 JP6253986 B2 JP 6253986B2
Authority
JP
Japan
Prior art keywords
seq
antibody
collection
germline
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013539286A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500725A (ja
JP2014500725A5 (https=
Inventor
ウルリンガー，シュテファーニエ
ティラー，トーマス
シュスター，イングリット
シュタルク，イボンヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MorphoSys GmbH
Original Assignee
MorphoSys GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MorphoSys GmbH filed Critical MorphoSys GmbH
Publication of JP2014500725A publication Critical patent/JP2014500725A/ja
Publication of JP2014500725A5 publication Critical patent/JP2014500725A5/ja
Application granted granted Critical
Publication of JP6253986B2 publication Critical patent/JP6253986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2013539286A 2010-11-19 2011-11-18 コレクション及びその使用方法 Active JP6253986B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41536710P 2010-11-19 2010-11-19
EP10191910 2010-11-19
US61/415,367 2010-11-19
EP10191910.8 2010-11-19
US201161494452P 2011-06-08 2011-06-08
US61/494,452 2011-06-08
PCT/EP2011/070473 WO2012066129A1 (en) 2010-11-19 2011-11-18 A collection and methods for its use

Publications (3)

Publication Number Publication Date
JP2014500725A JP2014500725A (ja) 2014-01-16
JP2014500725A5 JP2014500725A5 (https=) 2015-01-15
JP6253986B2 true JP6253986B2 (ja) 2017-12-27

Family

ID=44041472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013539286A Active JP6253986B2 (ja) 2010-11-19 2011-11-18 コレクション及びその使用方法

Country Status (18)

Country Link
US (3) US8728981B2 (https=)
EP (1) EP2640742B1 (https=)
JP (1) JP6253986B2 (https=)
KR (1) KR101938021B1 (https=)
CN (1) CN103237809B (https=)
AU (1) AU2011331129B2 (https=)
CA (1) CA2816558C (https=)
DK (1) DK2640742T3 (https=)
ES (1) ES2696548T3 (https=)
HR (1) HRP20181811T1 (https=)
IL (1) IL226364B (https=)
MX (1) MX353795B (https=)
NZ (1) NZ609707A (https=)
PL (1) PL2640742T3 (https=)
RU (1) RU2603080C2 (https=)
SG (2) SG189950A1 (https=)
WO (1) WO2012066129A1 (https=)
ZA (1) ZA201303566B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
MY191512A (en) * 2013-09-18 2022-06-28 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
EP3080158A4 (en) * 2013-12-09 2018-03-21 Adimab, LLC Polyclonal mixtures of antibodies, and methods of making and using them
BR112016014824A2 (pt) * 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
CA3014842A1 (en) 2016-02-19 2017-08-24 Morphosys Ag Antibodies for il-17c
ES2996699T3 (en) * 2016-04-12 2025-02-13 Medimmune Llc Immune repertoire mining
EP3538552B1 (en) 2016-11-14 2023-09-13 MorphoSys AG Fab molecules with a rodent hinge region and a non-rodent ch1 region
WO2019099454A2 (en) 2017-11-15 2019-05-23 Philippe Valadon Highly functional antibody libraries
KR20210013090A (ko) 2018-05-16 2021-02-03 모르포시스 아게 당단백질 vi를 표적으로 하는 항체
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
US20230183675A1 (en) 2020-05-20 2023-06-15 Institut Curie Synthetic Single Domain Library
WO2021250017A1 (en) 2020-06-08 2021-12-16 Immundiagnostik Ag Improved method and test system for in-vitro determination of drug antibodies in blood
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
US20250206819A1 (en) 2022-03-22 2025-06-26 Morphosys Ag Deimmunized antibodies specific for cd3
WO2024236163A1 (en) 2023-05-17 2024-11-21 Morphosys Ag T cell receptor beta constant region 2 (trbc2) antibodies
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
WO1990014443A1 (en) 1989-05-16 1990-11-29 Huse William D Co-expression of heteromeric receptors
US6291159B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
CA2016842A1 (en) 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992015678A1 (en) 1991-03-01 1992-09-17 Stratagene Pcr generated dicistronic dna molecules for producing antibodies
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
WO1993003151A1 (en) 1991-08-10 1993-02-18 Medical Research Council Treatment of cell populations
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
WO1995011998A1 (en) 1993-10-26 1995-05-04 United Biomedical, Inc. Structured synthetic antigen libraries as diagnostics, vaccines and therapeutics
US20010049107A1 (en) 1994-01-31 2001-12-06 Boston University Polyclonal antibody libraries
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
GB9603507D0 (en) 1996-02-20 1996-04-17 Isis Innovation Antibody variants
CA2297070A1 (en) 1997-08-01 1999-02-11 Morphosys Ag Novel method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly)peptide complex
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
WO2000052054A2 (en) 1999-03-01 2000-09-08 Genentech, Inc. Antibodies for cancer therapy and diagnosis
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
IL136459A0 (en) 2000-05-30 2001-06-14 Galim Galil Immunology Ltd Antibody library
ES2430857T3 (es) 2000-12-18 2013-11-22 Dyax Corp. Bibliotecas focalizadas de paquetes genéticos
US7117096B2 (en) 2001-04-17 2006-10-03 Abmaxis, Inc. Structure-based selection and affinity maturation of antibody library
DK1438400T3 (da) 2001-10-01 2009-10-05 Dyax Corp Flerkædede eukaryote display-vektorer og anvendelser deraf
GB0130267D0 (en) 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
EP1456237A2 (en) 2001-12-21 2004-09-15 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Method for cloning of variable domain sequences
US7244592B2 (en) 2002-03-07 2007-07-17 Dyax Corp. Ligand screening and discovery
US8206977B2 (en) 2002-07-30 2012-06-26 Morphosys Ag Tricistronic vectors and uses therefor
US8557743B2 (en) 2002-09-05 2013-10-15 Dyax Corp. Display library process
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
US20120202710A1 (en) 2003-09-09 2012-08-09 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
WO2005094159A2 (en) 2003-11-12 2005-10-13 Oncomab Gmbh Methods of identifying neoplasm-specific antibodies and uses thereof
WO2005071112A2 (en) 2004-01-26 2005-08-04 Isis Innovation Ltd Molecular analysis
DE502005011243D1 (de) 2004-05-26 2011-05-26 Fraunhofer Ges Forschung Isolation allergen-spezifischer immunoglobulin-gene aus humanen b-zellen von atopikern
CA2572961C (en) 2004-07-06 2016-08-16 Bioren, Inc. Universal antibody libraries
US7977050B2 (en) 2004-09-02 2011-07-12 Bioarray Solutions, Ltd. Nucleic acid amplification with integrated multiplex detection
US20060078898A1 (en) 2004-10-12 2006-04-13 Curry Bo U Methods and compositions for reducing label variation in array-based comparative genome hybridization assays II
US8551920B2 (en) 2005-02-01 2013-10-08 Morpho Sys AG Libraries and methods for isolating antibodies
RU2311927C2 (ru) * 2005-08-15 2007-12-10 Федеральное государственное унитарное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека" КОМБИНАТОРНАЯ ФАГМИДНАЯ БИБЛИОТЕКА ОДНОЦЕПОЧЕЧНЫХ АНТИТЕЛ ЧЕЛОВЕКА, ОБОГАЩЕННАЯ АНТИТЕЛАМИ ПРОТИВ ВИРУСА ОСПОВАКЦИНЫ, РЕКОМБИНАНТНАЯ ФАГМИДНАЯ ДНК pHEN-2A8, СОДЕРЖАЩАЯ УНИКАЛЬНЫЙ ГЕН ОДНОЦЕПОЧЕЧНОГО АНТИТЕЛА ЧЕЛОВЕКА, СПОСОБНОГО НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ, И ИСКУССТВЕННОЕ ОДНОЦЕПОЧЕЧНОЕ АНТИТЕЛО ЧЕЛОВЕКА 2A8, СПОСОБНОЕ НЕЙТРАЛИЗОВАТЬ ВИРУС ОСПОВАКЦИНЫ И ВИРУС ОСПЫ КОРОВ
EP1957531B1 (en) 2005-11-07 2016-04-13 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1979378B1 (en) 2005-12-20 2012-07-25 MorphoSys AG Novel collection of hcdr3 regions and uses therefor
WO2007130520A2 (en) 2006-05-04 2007-11-15 Abmaxis Inc. Cross-species and multi-species display systems
EP1918302A3 (en) * 2006-05-18 2009-11-18 AvantGen, Inc. Methods for the identification and the isolation of epitope specific antibodies
CN101772574B (zh) 2007-08-21 2016-01-06 莫佛塞斯公司 改良的用于二硫键形成的方法
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
JP2011507519A (ja) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法
EP2088432A1 (en) * 2008-02-11 2009-08-12 MorphoSys AG Methods for identification of an antibody or a target
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
EP2100970B1 (en) 2008-03-13 2017-05-10 National Institute of Immunology Ig genes specific oligonucleotides and uses thereof
EP2331570B1 (en) 2008-09-10 2014-08-27 Philochem AG Display library for antibody selection
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2010130824A2 (en) * 2009-05-15 2010-11-18 Morphosys Ag Collections and uses thereof
SG175407A1 (en) 2009-05-29 2011-11-28 Morphosys Ag A collection and methods for its use
EP2528944B1 (en) 2010-01-29 2015-08-12 MorphoSys AG Rodent combinatorial antibody libraries

Also Published As

Publication number Publication date
RU2013126025A (ru) 2014-12-27
RU2603080C2 (ru) 2016-11-20
ZA201303566B (en) 2014-07-30
US8728981B2 (en) 2014-05-20
HRP20181811T1 (hr) 2018-12-28
MX353795B (es) 2018-01-30
EP2640742A1 (en) 2013-09-25
SG10201509257VA (en) 2015-12-30
US20130236902A1 (en) 2013-09-12
US20120129717A1 (en) 2012-05-24
MX2013005614A (es) 2013-11-21
SG189950A1 (en) 2013-06-28
CA2816558C (en) 2020-12-29
AU2011331129A1 (en) 2013-05-23
US9541559B2 (en) 2017-01-10
US8367586B2 (en) 2013-02-05
WO2012066129A1 (en) 2012-05-24
IL226364A0 (en) 2013-07-31
NZ609707A (en) 2014-12-24
CN103237809A (zh) 2013-08-07
KR101938021B1 (ko) 2019-01-11
PL2640742T3 (pl) 2019-01-31
DK2640742T3 (en) 2018-12-03
CN103237809B (zh) 2016-09-07
CA2816558A1 (en) 2012-05-24
AU2011331129B2 (en) 2016-10-06
JP2014500725A (ja) 2014-01-16
IL226364B (en) 2020-11-30
EP2640742B1 (en) 2018-08-15
US20140206575A1 (en) 2014-07-24
ES2696548T3 (es) 2019-01-16
KR20140015274A (ko) 2014-02-06

Similar Documents

Publication Publication Date Title
JP6253986B2 (ja) コレクション及びその使用方法
US10647757B2 (en) Collection and methods for its use
KR20200020819A (ko) 개과 항체 라이브러리
HK1187626B (en) A collection and methods for its use
HK1187626A (en) A collection and methods for its use
GB2616707A (en) Methods
HK1168635B (en) A collection and methods for its use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171023

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171129

R150 Certificate of patent or registration of utility model

Ref document number: 6253986

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250